Notably, we found that intranasal administration of PNA-33 markedly reduces lung fibrosis, as indicated by a significant decrease in collagen content and fibrogenic gene expression (Col1a1 and Acta2) compared with mice treated with scrambled control (Figure 3, D–F). The gene discussed is ACTA2; the disease is pulmonary fibrosis.